Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
AMERISAFE's updated analyst narrative centers on a revised fair value estimate, with the modeled price target moving from US$38.67 to US$36.67. Recent research links this shift to refreshed assumptions on valuation and execution, as analysts weigh how the company balances growth initiatives, profitability, and capital discipline, rather than reacting to a single event. As you read on, you will see how these target moves fit into the broader story around AMERISAFE and what to watch as the narrative continues to evolve.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Even as price targets are revised, coverage from firms like Truist and Citizens signals that AMERISAFE remains on analyst radar, which can help investors track how the story around its workers' compensation niche evolves over time.
-
Analysts appear focused on how AMERISAFE manages the mix of growth initiatives, profitability, and capital discipline, suggesting that execution on underwriting quality and expense control is still central to the long term thesis for the stock.
🐻 Bearish Takeaways
-
Truist lowered its AMERISAFE price target by US$2, while Citizens reduced its target by US$5, reflecting more cautious valuation assumptions and a tighter margin of safety around future execution.
-
The direction of these target changes hints that analysts are weighing potential headwinds for AMERISAFE, including how growth opportunities compare with risks to returns on capital and the predictability of earnings over time.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for AMERISAFE. See which could impact your investment.
How This Changes the Fair Value For AMERISAFE
-
Fair value revised from US$38.67 to US$36.67, a reduction of about US$2.00 that aligns with updated assumptions.
-
Revenue growth adjusted from 4.09% to 4.45% in the latest model.
-
Net profit margin reduced from 10.03% to 8.20% in the refreshed forecasts.
-
Future P/E moved from 23.75x to 25.24x in the updated valuation work.
-
Discount rate refined from 6.98% to 7.11% in the current framework.
Never Miss an Update: Follow The Narrative
Narratives connect AMERISAFE's business story with analyst forecasts and an evolving view of fair value, updating as new data and events come through. They help you see how individual data points fit into a bigger, ongoing thesis.
Head over to the Simply Wall St Community and follow the Narrative on AMERISAFE to stay up to date on:
-
How policy count growth, voluntary premium growth and agent partnerships are being used to expand AMERISAFE's addressable market and support revenue.
-
The role of technology investment, high renewal retention, disciplined risk selection and capital returns in supporting earnings stability.
-
Key pressure points such as industry pricing pressure, rising medical severity costs, moderating audit premium and higher expense ratios that could weigh on growth and profitability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMSF .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
